Literature DB >> 25282282

Decreased cortical thickness in drug naïve first episode schizophrenia: in relation to serum levels of BDNF.

Xueqin Song1, Meina Quan2, Luxian Lv3, Xue Li4, Lijuan Pang4, David Kennedy2, Steven Hodge2, Amy Harrington2, Douglas Ziedonis2, Xiaoduo Fan5.   

Abstract

This study was to examine cortical thickness in drug naïve, first episode schizophrenia patients, and to explore its relationship with serum levels of brain-derived neurotrophic factor (BDNF). Forty-five drug naive schizophrenia patients and 28 healthy controls were enrolled in the study. Freesurfer was used to parcellate cortical regions, and vertex-wise group analysis was used for whole brain cortical thickness. The clusters for the brain regions that demonstrated group differences were extracted, and the mean values of thickness were calculated. Serum levels of BDNF were measured using enzyme-linked immunosorbent assay (ELISA). After controlling for age and gender, significantly thinner cortical thickness was found in left insula and superior temporal gyrus in the patient group compared with the healthy control group (HC group) (p's < 0.001). Lower serum levels of BDNF were also found in the patient group compared with the HC group (p = 0.001). Correlation analysis showed a significant positive relationship between thickness of left insula and serum levels of BDNF within the HC group (r = 0.396, p = 0.037) but there was no such relationship within the patient group (r = 0.035, p = 0.819). Cortical thinning is present in drug naïve, first episode schizophrenia patients, indicating neurodevelopmental abnormalities at the onset of schizophrenia. Left insula might be an imaging biomarker in detecting the impaired protective role of neurotrophic factor for the brain development in schizophrenia.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  BDNF; Cortical thickness; First episode schizophrenia

Mesh:

Substances:

Year:  2014        PMID: 25282282     DOI: 10.1016/j.jpsychires.2014.09.009

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  14 in total

1.  Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.

Authors:  Eric Plitman; Raihaan Patel; Jun Ku Chung; Jon Pipitone; Sofia Chavez; Francisco Reyes-Madrigal; Gladys Gómez-Cruz; Pablo León-Ortiz; M Mallar Chakravarty; Camilo de la Fuente-Sandoval; Ariel Graff-Guerrero
Journal:  Neuropsychopharmacology       Date:  2016-06-08       Impact factor: 7.853

2.  The relationship between subcortical brain volume and striatal dopamine D2/3 receptor availability in healthy humans assessed with [11 C]-raclopride and [11 C]-(+)-PHNO PET.

Authors:  Fernando Caravaggio; Jun Ku Chung; Eric Plitman; Isabelle Boileau; Philip Gerretsen; Julia Kim; Yusuke Iwata; Raihaan Patel; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Hum Brain Mapp       Date:  2017-07-28       Impact factor: 5.038

Review 3.  (Micro)Glia as Effectors of Cortical Volume Loss in Schizophrenia.

Authors:  Allyson P Mallya; Ariel Y Deutch
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

4.  The BDNF Val66Met polymorphism is associated with structural neuroanatomical differences in young children.

Authors:  Kaja K Jasińska; Peter J Molfese; Sergey A Kornilov; W Einar Mencl; Stephen J Frost; Maria Lee; Kenneth R Pugh; Elena L Grigorenko; Nicole Landi
Journal:  Behav Brain Res       Date:  2017-03-27       Impact factor: 3.332

5.  Positive symptoms associate with cortical thinning in the superior temporal gyrus via the ENIGMA Schizophrenia consortium.

Authors:  E Walton; D P Hibar; T G M van Erp; S G Potkin; R Roiz-Santiañez; B Crespo-Facorro; P Suarez-Pinilla; N E M Van Haren; S M C de Zwarte; R S Kahn; W Cahn; N T Doan; K N Jørgensen; T P Gurholt; I Agartz; O A Andreassen; L T Westlye; I Melle; A O Berg; L Mørch-Johnsen; A Faerden; L Flyckt; H Fatouros-Bergman; E G Jönsson; R Hashimoto; H Yamamori; M Fukunaga; A Preda; P De Rossi; F Piras; N Banaj; V Ciullo; G Spalletta; R E Gur; R C Gur; D H Wolf; T D Satterthwaite; L M Beard; I E Sommer; S Koops; O Gruber; A Richter; B Krämer; S Kelly; G Donohoe; C McDonald; D M Cannon; A Corvin; M Gill; A Di Giorgio; A Bertolino; S Lawrie; T Nickson; H C Whalley; E Neilson; V D Calhoun; P M Thompson; J A Turner; S Ehrlich
Journal:  Acta Psychiatr Scand       Date:  2017-03-29       Impact factor: 6.392

Review 6.  A Meta-Analysis of Brain-Derived Neurotrophic Factor Effects on Brain Volume in Schizophrenia: Genotype and Serum Levels.

Authors:  Anthony O Ahmed; Samantha Kramer; Naama Hofman; John Flynn; Marie Hansen; Victoria Martin; Anilkumar Pillai; Peter F Buckley
Journal:  Neuropsychobiology       Date:  2021-03-11       Impact factor: 2.328

7.  Brain-derived neurotrophic factor promoter methylation and cortical thickness in recurrent major depressive disorder.

Authors:  Kyoung-Sae Na; Eunsoo Won; June Kang; Hun Soo Chang; Ho-Kyoung Yoon; Woo Suk Tae; Yong-Ku Kim; Min-Soo Lee; Sook-Haeng Joe; Hyun Kim; Byung-Joo Ham
Journal:  Sci Rep       Date:  2016-02-15       Impact factor: 4.379

8.  Structural Covariance Analysis Reveals Differences Between Dancers and Untrained Controls.

Authors:  Falisha J Karpati; Chiara Giacosa; Nicholas E V Foster; Virginia B Penhune; Krista L Hyde
Journal:  Front Hum Neurosci       Date:  2018-09-25       Impact factor: 3.169

9.  Brain-derived neurotrophic factor increase during treatment in severe mental illness inpatients.

Authors:  G L Nuernberg; B Aguiar; G Bristot; M P Fleck; N S Rocha
Journal:  Transl Psychiatry       Date:  2016-12-13       Impact factor: 6.222

10.  BDNF Serum Levels are Associated With White Matter Microstructure in Schizophrenia - A Pilot Study.

Authors:  Christine Hammans; Kristina Neugebauer; Vinod Kumar; Lea Mevissen; Melanie A Sternkopf; Ana Novakovic; Tobias Wensing; Ute Habel; Ted Abel; Thomas Nickl-Jockschat
Journal:  Front Psychiatry       Date:  2020-02-21       Impact factor: 4.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.